Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3105
Gene Symbol: HLA-A
HLA-A
0.010 Biomarker disease BEFREE HLA-A,B,C phenotyping was performed on 95 patients with geographic tongue to determine whether there is an increased frequency of any particular allele in this condition. 12735333 1980
Entrez Id: 4318
Gene Symbol: MMP9
MMP9
0.020 AlteredExpression disease BEFREE Matrix metalloproteinase 9 (MMP-9) was selectively upregulated in the erythema migrans skin lesions of patients with acute Lyme disease. 17403874 2007
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.030 GeneticVariation disease BEFREE IL-6 and TNFA polymorphisms were not associated with BMG in the univariate and multivariate analyses. 17850436 2007
Entrez Id: 3106
Gene Symbol: HLA-B
HLA-B
0.010 GeneticVariation disease BEFREE HLA-B*58 allele was more frequently found in GT. 25176018 2015
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.030 GeneticVariation disease BEFREE IL6 allele G rs2069843 polymorphism was associated with BMG in the dominant model. 27810384 2017
Entrez Id: 1950
Gene Symbol: EGF
EGF
0.010 Biomarker disease BEFREE EGF and VEGF also seem to be involved in the pathophysiology of GT. 28178402 2017
Entrez Id: 27306
Gene Symbol: HPGDS
HPGDS
0.010 Biomarker disease BEFREE Among the 124 antibiotic-treated patients, 53% with culture-proven erythema migrans (EM) had IgG responses to recombinant glutathione S-transferase (GST)-Arp, as did 59% of the patients with facial palsy and 68% of those with Lyme arthritis. 15845501 2005
Entrez Id: 373156
Gene Symbol: GSTK1
GSTK1
0.010 Biomarker disease BEFREE Among the 124 antibiotic-treated patients, 53% with culture-proven erythema migrans (EM) had IgG responses to recombinant glutathione S-transferase (GST)-Arp, as did 59% of the patients with facial palsy and 68% of those with Lyme arthritis. 15845501 2005
Entrez Id: 133482
Gene Symbol: SLCO6A1
SLCO6A1
0.010 Biomarker disease BEFREE Among the 124 antibiotic-treated patients, 53% with culture-proven erythema migrans (EM) had IgG responses to recombinant glutathione S-transferase (GST)-Arp, as did 59% of the patients with facial palsy and 68% of those with Lyme arthritis. 15845501 2005
Entrez Id: 3458
Gene Symbol: IFNG
IFNG
0.030 AlteredExpression disease BEFREE Among the 27 patients who had erythema migrans alone with no associated signs or symptoms, the major cytokines expressed in perivascular infiltrates of T cells and macrophages were the pro-inflammatory cytokine interferon-gamma and the anti-inflammatory cytokine interleukin-10. 11121150 2000
Entrez Id: 2919
Gene Symbol: CXCL1
CXCL1
0.010 AlteredExpression disease BEFREE Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). 18171218 2008
Entrez Id: 6348
Gene Symbol: CCL3
CCL3
0.010 AlteredExpression disease BEFREE Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). 18171218 2008
Entrez Id: 6351
Gene Symbol: CCL4
CCL4
0.010 AlteredExpression disease BEFREE Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). 18171218 2008
Entrez Id: 4283
Gene Symbol: CXCL9
CXCL9
0.020 AlteredExpression disease BEFREE Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). 18171218 2008
Entrez Id: 3627
Gene Symbol: CXCL10
CXCL10
0.020 AlteredExpression disease BEFREE Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). 18171218 2008
Entrez Id: 6373
Gene Symbol: CXCL11
CXCL11
0.010 AlteredExpression disease BEFREE Compared with the EM lesions of B. afzelii-infected Austrian patients, those of B. burgdorferi-infected US patients had significantly higher mRNA levels of chemokines associated with activation of macrophages, including chemoattractants for neutrophils (CXCL1), macrophages (CCL3 and CCL4), and T helper 1 cells (CXCL9, CXCL10, and CXCL11). 18171218 2008
Entrez Id: 10563
Gene Symbol: CXCL13
CXCL13
0.010 Biomarker disease BEFREE Demographic variables, CSF findings, and history of erythema migrans were assessed as possible predictors for CXCL13 CSF concentrations by a general linear model. 29705691 2018
Entrez Id: 3458
Gene Symbol: IFNG
IFNG
0.030 AlteredExpression disease BEFREE Early in the illness, patients with EM carrying 1805GG, primarily those infected with B burgdorferi 16S-23S ribosomal spacer RNA intergenic type 1 (RST1) strains, had higher serum levels of interferon-γ (IFNγ), CXCL9, and CXCL10 and had more severe infection than EM patients carrying the 1805TG/TT polymorphism. 22246581 2012
Entrez Id: 4283
Gene Symbol: CXCL9
CXCL9
0.020 AlteredExpression disease BEFREE Early in the illness, patients with EM carrying 1805GG, primarily those infected with B burgdorferi 16S-23S ribosomal spacer RNA intergenic type 1 (RST1) strains, had higher serum levels of interferon-γ (IFNγ), CXCL9, and CXCL10 and had more severe infection than EM patients carrying the 1805TG/TT polymorphism. 22246581 2012
Entrez Id: 3627
Gene Symbol: CXCL10
CXCL10
0.020 Biomarker disease BEFREE Early in the illness, patients with EM carrying 1805GG, primarily those infected with B burgdorferi 16S-23S ribosomal spacer RNA intergenic type 1 (RST1) strains, had higher serum levels of interferon-γ (IFNγ), CXCL9, and CXCL10 and had more severe infection than EM patients carrying the 1805TG/TT polymorphism. 22246581 2012
Entrez Id: 7096
Gene Symbol: TLR1
TLR1
0.010 AlteredExpression disease BEFREE Early in the illness, patients with EM carrying 1805GG, primarily those infected with B burgdorferi 16S-23S ribosomal spacer RNA intergenic type 1 (RST1) strains, had higher serum levels of interferon-γ (IFNγ), CXCL9, and CXCL10 and had more severe infection than EM patients carrying the 1805TG/TT polymorphism. 22246581 2012
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.010 Biomarker disease BEFREE EGF and VEGF also seem to be involved in the pathophysiology of GT. 28178402 2017
Entrez Id: 11331
Gene Symbol: PHB2
PHB2
0.010 Biomarker disease BEFREE Examination of sera from patients with Lyme disease revealed that antibodies to P22 are rarely detected in patients with early-stage disease characterized by erythema migrans (2 of 20), and 35% of the patients with late-stage disease characterized by arthritis (9 of 26) developed antibodies to P22. 8027338 1994
Entrez Id: 11258
Gene Symbol: DCTN3
DCTN3
0.010 Biomarker disease BEFREE Examination of sera from patients with Lyme disease revealed that antibodies to P22 are rarely detected in patients with early-stage disease characterized by erythema migrans (2 of 20), and 35% of the patients with late-stage disease characterized by arthritis (9 of 26) developed antibodies to P22. 8027338 1994
Entrez Id: 1778
Gene Symbol: DYNC1H1
DYNC1H1
0.010 Biomarker disease BEFREE Examination of sera from patients with Lyme disease revealed that antibodies to P22 are rarely detected in patients with early-stage disease characterized by erythema migrans (2 of 20), and 35% of the patients with late-stage disease characterized by arthritis (9 of 26) developed antibodies to P22. 8027338 1994